Go to Health Care Provider version
| Diagnosis | Solid or brain tumour with a change in the RET gene | Study Status | Closed to enrollment |
| Phase | I/II |
| Age | Child, Adult - (6 Months to 21 Years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Selpercatinib is taken by mouth (capsules or oral suspension)
Participants <18 years of age may be offered to try a tablet formulation of selpercatinib. |
| Last Posted Update | 2024-09-10 |
| ClinicalTrials.gov # | NCT03899792 |
International Sponsor
Loxo Oncology, Inc.Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel MorgensternCentres
Study Description
This clinical trial studies the side effects and how well selpercatinib (a medication taken by mouth) works in treating patients with solid tumors and brain tumours with a change in a gene called RET.
Selpercatinib may stop the growth of cancer cells with RET gene changes by blocking the RET enzymes needed for cell growth.
Inclusion Criteria
- Age between 6 months and 21 years
- Solid tumors and brain tumours with a change in a gene called RET
- Cancer that has come back (relapse) or is not improving despite treatment (progression)
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
